As part of the consultation meeting, representatives from two of the important stakeholder groups discussed within their groups about what they thought were the most important issues going forward.
Clinicians: The focus of research was a key theme in the discussion, in particular, how computational models must be relevant, and that a highly developed model ill-suited to the clinical decision-making pipeline may not be very useful. Also, the ability to feedback long-term data on patients was seen as important for model development, and in particular to focus on disease prevention. The interaction between the clinician and the model is crucial, in particular, how the information on prediction (as well as uncertainty estimation) is conveyed to the user. It was suggested that the scope for the model in decision-making should be clearly defined, the analogy given was that of the autopilot. While models can provide valuable information throughout the decision-making pipeline, clinicians will need to make final decisions.
Industry: Sustainability strategies and business models must be clearly defined from the start of a research initiative, if it is going to attract investment to make it a reality. The standardisation of data handling and model definition will enable greater progress in model development. The industry representatives also mentioned the fact that regulations differ between countries, and even between hospitals, and that this challenge must be overcome for provide a scalable business model. It was also suggested that while Health and Wellness (i.e. preventative medicine) came up in many discussions during the meeting, this area has not traditionally been a topic pursued by industry (which focuses on disease treatment).
FDA confirms its investment in modeling and simulation for improving drug development
Scott Gottlieb commissioner of the USA Food & Drug Administration has recently written an article for the FDA Blog “FDA Voice” on the impact of the 21st Century Cures Act, which authorised $6.3 billion in additional funding, part of which is dedicated to research and drug development.
VPHi-Alliance research WG: report on the recent activities
On 23 June 2017 the Research WG had its second meeting of the year.
PIC to train 15 innovation leaders in Computational Cardiology
PIC, a recently funded European ITN, will train a cohort of 15 future innovation leaders able to articulate and materialise the vision of Personalised In-silico Cardiology (PIC), where healthcare is guided by in silico models.